Skin Analytics specialises in cancer screening for melanoma and non-melanoma skin cancers. The company invested heavily in technology with the potential to disrupt the process of diagnosis and management of skin cancer, and has validated their proprietary technology in two large studies.
Skin Analytics won the 2018 UKBAA Best AI Investment, 2018 Advance Queensland Ignite Grant, and have received several other awards and grants. They are expanding further, into public and private healthcare markets, in the UK, Australia, and New Zealand.
The company has entered into agreements in primary care, and has commercial contracts with private medical insurers and providers.
Skin Analytics raised £1.6m funding in 2018, from RYSE and other investors, to finalise the first prospective clinical study in applying AI to dermatology, secure regulatory approvals, and develop the high-calibre team to deploy the technology into patient care pathways.
They are now raising their Series A, securing US FDA Breakthrough Devices Designation, and preparing for their next expansion phase which may attract US capital in follow on rounds.
“RYSE and DH.L have given us great access to leading NHS initiatives, those behind them, as well as the financial support needed to get our technology to the point it will positively impact patients and the healthcare service"
Neil Daly, CEO Skin Analytics
LiveSmart provides pathology-based health assessments, digital health data tracking, reporting and behavioural change programmes, alongside one-to-one health coaching services led by their medical team.
LiveSmart participated in the RYSE Early Stage Investment Programme to gain the further technological validation of their product through the panel of DH.L reviewers and to benefit from RYSE’s experienced network.
The company's development focus is via commercial partnerships with health insurers, other intermediaries, in additional to a direct to consumer model. Their partnership with AXA PPP has provided LiveSmart a mark of pre-approval and global access to over 100 million customers.
LiveSmart raised £1.25m funding in 2018, from RYSE and other investors, to expand sales into other geographical jurisdictions, secure additional long-term partnerships in the insurance market, and to further improve their product.
They've now raised an additional £1.8m for further geographical expansion, strengthen partnerships internationally, and develop direct sales. RYSE and several other investors have committed follow-on capital to this bridge round.
“Navigating the digital healthcare landscape is complex. Choosing to work with specialists like RYSE and DH.L was a no brainer for us. Their deep knowledge and understanding of the health and funding environment will continue to be a major advantage for us moving forward”
Alex Heaton, CEO LiveSmart
Digi.me is an ethical and sustainable way for individuals to take control of their data and privately share with data-driven apps and services. Working toward a decentralised future for data privacy and security.
Data can be added to a library from thousands of different sources, including social, financial, and healthcare. The user owns the library and keeps it on their choice of secure cloud storage. The user can share data with 3rd parties directly from their device, enabling complete control over privacy.
Based in the UK, digi.me has grown to over 60 people with offices in France, Iceland, Australia, and the US.
Digi.me raised £18 million funding in this round. They have a fully developed product that is currently being used by dozens of market partners including Facebook.
“It has become clear that society needs solutions that empower individuals and governments to do more with greater access to data without infringing on personal privacy and freedom”
Knok Healthcare is a simplified telemedicine solution for virtual consultations through a combination of triage, scheduling, record keeping, and integration with healthcare providers.
Knok Healthcare’s product, Panacea, aims to be the reference white label provider for virtual consultations. Panacea incorporates clinical support, for both patient and clinician (integrated web and mobile apps), which integrate seamlessly into the existing patient journey and connect with enterprise systems.
The company is active, in both Europe and the Americas, and has entered into commercial contracts with private medical insurers and corporate providers.
Knok Healthcare raised funding in this round, from RYSE and other investors, to further develop Panacea for use in the European market.
“RYSE and DH.L gives us great access to UK based clinical and technology talent. We are excited to work with RYSE given their previous experience supporting companies with medical insurer and corporate distribution channels”
José Bastos, CEO Knok Healthcare
Log my Care
Log my Care is a care management software that is improving care coordination and communication in social care. Specifically, it has been designed for and by carers.
Log my Care’s product enables care planning from a smart management system and saves a carer's time with an easy to use mobile app. It runs on most mobile devices and is designed to allow carers to easily record and coordinate care on the go.
The company has experienced rapid organic growth in the UK and has entered into agreements with several care home groups.
Log my Care raised £600k funding in this round, from RYSE and other investors, to further develop their freemium product for use in the European market.
“RYSE and DH.L provide access to invaluable healthcare providers and payors. We look forward to working with RYSE in the next phase of our growth and distribution in order to bring social care into the 21st century”
Sam Hussain, CEO Log my Care
Firza provides a digital workforce based solution that addresses the medication management needs within primary healthcare, including GP surgeries, community pharmacies, prisons, and care homes.
Firza’s product allows primary healthcare practices to adjust to changes in demand and to respond with a solution that integrates into the team’s existing workflow. They have utilised professional skills, experience, and technology to validate opportunities for cost efficiencies and value-based healthcare.
The company has demonstrated significant revenue growth and has entered into agreements with multinational healthcare providers.
Firza is raising £500k funding in this round, from RYSE and other investors, to further develop their Robotic Process Automation, Artificial Intelligence, and scalability of their product.
“RYSE and DH.L are experienced in accessing the primary healthcare and medical insurer markets in the UK. We’re delighted to be working with RYSE in the next phase of our growth, in order to deliver technology and digital services for the modern day General Practice”
Asim Mirza, CEO Firza
MediShout provides mobile and web based healthcare reporting software to quickly, and accurately, report logistical issues to increase the quality and reduce the cost of healthcare delivery.
MediShout’s product allows healthcare providers to prioritise problems and predictive software analytics prevent equipment issues! The company launched their application with healthcare providers and works with suppliers to integrate communication in the clinical setting.
The company is active in NHS hospitals, and clinics, and allows healthcare providers to instantly report any issues encountered. Users simply select their location, describe their problem, add a photo, and press Shout!
MediShout raised funding in this round, from RYSE and other investors, has been awarded an Innovate UK grant, and is a member of the NHS Clinical Entrepreneur programme.
“RYSE has provided us with a first seed round of funding to develop our reach into the broader healthcare market. We are excited to work with them - to address some of the key issues in our healthcare supply chain - for the benefit of our valued healthcare providers and patients”
Ashish Kalraiya, CEO MediShout